Clinical Trial Update: Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of trebananib for persistent or recurrent endometrial cancer has completed, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Adenocarcinoma
• Endometrial Adenosquamous Carcinoma
• Endometrial Clear Cell Adenocarcinoma
• Endometrial Endometrioid Adenocarcinoma with Squamous Differentiation
• Endometrial Serous Adenocarcinoma
• Endometrioid Stromal Sarcoma
• Uterine Corpus Carcinoma

Drugs mentioned

• Trebananib (trebananib)

Snippet

Sponsor: Gynecologic Oncology Group | Conditions: Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2017-11-29